- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01896544
Cholecalciferol Supplementation for Sepsis in the ICU (CSI)
The Effect of Cholecalciferol Supplementation on Vitamin D Status in Sepsis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sepsis is a clinical syndrome that complicates severe infections. It is characterized by the cardinal signs of inflammation (e.g. vasodilation, leukocytosis, increased microvascular permeability) occurring in tissues that are remote from the site of an infection. Current theories about the onset and progression of the sepsis syndrome focus on dysregulation of inflammatory responses, including the possibility that a massive and uncontrolled release of pro-inflammatory mediators initiates a chain of events that lead to widespread tissue injury. The degree of immune dysfunction is thought to correlate with the severity of the sepsis syndrome. Sepsis syndrome can range from sepsis, to severe sepsis, septic shock, and multiple organ dysfunction syndrome (MODS). The mortality associated with each of these is estimated to be 16%, 20%, 46%, >80%, respectively. The annual incidence of sepsis syndrome exceeds 1.6 million cases in the United States alone.
Recently, cells of the innate and adaptive immune system have been shown to express the vitamin D receptor. Vitamin D appears to be necessary for interferon-γ dependent T cell responses to infection. In low vitamin D states, dysfunctional macrophage activity becomes evident. Vitamin D is also an important link between Toll Like Receptor (TLR) activation and antibacterial response. Human macrophages stimulated by TLR induce: 1) vitamin D receptor expression; 2) conversion of 25(OH)D to its most biologically active form of 1,25-dihydroxyvitamin D; and 3) production of cathelicidin (LL-37), an endogenous antimicrobial peptide with potent activity against bacteria, viruses, fungi, and mycobacteria. LL-37 is highly expressed in both the plasma and at natural barrier sites (e.g. skin, gut, lungs) and may represent an important first-line of defense for the innate immune system.
In humans, cholecalciferol (vitamin D3) is either obtained through the diet or synthesized by skin upon exposure to ultraviolet B (UVB) radiation. Cholecalciferol is converted to 25(OH)D in the liver or by cells of the immune system. Serum 25(OH)D can be measured with relative ease and is the most abundant vitamin D metabolite. It is therefore, often used as a proxy for total body vitamin D status and 25(OH)D levels <30 ng/mL characterize an insufficient state. A growing body of evidence suggests that a significant proportion (50-90%) of critically ill patients may have insufficient 25(OH)D levels during admission to the intensive care unit (ICU). 25(OH)D insufficiency, in turn, appears to be associated with a higher risk of mortality in critically ill patients. However, randomized, placebo-controlled trials (RCTs) aimed at studying the effect of vitamin D supplementation in critical illness are limited and have largely focused on superficial assessments of vitamin D status. While it is known that septic patients have nearly universally low 25(OH)D levels and that the vitamin D levels are inversely correlated with the severity of sepsis, little is known regarding the effects of vitamin supplementation in this patient cohort. Therefore, our goal is to determine whether vitamin D supplementation in patients highly suspected of sepsis syndrome may be effective in optimizing 25(OH)D levels and in improving host production of the antimicrobial polypeptide LL-37.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- English or Spanish speaking
- Within 24 hours of a suspected diagnosis of sepsis
Meeting criteria for sepsis (defined as suspected or confirmed infection AND at least one diagnostic criteria in each of the following groupings):
Vital signs:
- Temperature: >38.3 Celsius (C) or <36 Celsius (C)
- Heart rat e: >90/min, or >2 standard deviation above normal
- Tachypnea (>20 breaths per minute)
- Altered mental status
- Positive fluid balance (>20 mL/Kg over 24 hrs)
- Glucose >140 mg/dL in the absence of diabetes mellitus
Inflammatory markers:
- white blood cell (WBC): >12,000 or <4,000
- Normal WBC count with >10% immature forms
- c-reactive protein (CRP) >2 standard deviation above normal value
- Pro- calcitonin >2 standard deviation above normal value
Hemodynamic
- Systolic blood pressure (SBP) <90 millimeters mercury (mmHg), Mean Arterial Pressure (MAP) <70mmHg or SBP decrease >40mmHg
- Vasopressor therapy to maintain MAP >65mmHg
Organ dysfunction
- Arterial hypoxemia arterial oxygen partial pressure/fractional inspired oxygen (PaO2/FiO2) <300
- Acute Oliguria (UoP <0.5 mL/Kg/hr for at least 2 hours)
- Cr increase >0.5 mg/dL
- Coagulopathy: internationals normalized ratio (INR) >1.5 or a-partial prothrombin time (aPTT) >60 sec
- Thrombocytopenia: Platelet (PLT) <100 thousand (K)
- Hyperbilirubinemia: Total Bilirubin (Tbili) >4 mg/dL
Tissue perfusion
- Lactate >2 mmol/L
- Decrease cap refill or mottling
Exclusion Criteria:
- Pregnant females or immediate post-partum status
- "Comfort measures only" status
- Inability to provide informed consent or have a surrogate consent
- History of renal stones within the past year
- History of hypercalcemia within the past year
- Baseline serum total calcium >10 mg/dL
- Established diagnosis associated with increased risk of hypercalcemia (e.g. metastatic cancer, sarcoidosis, multiple myeloma, primary hyperparathyroidism)
- History of severe anemia (Hematocrit <25%)
- Medications that affect vitamin D metabolism (e.g. antiepileptics, tuberculosis medication
- Already enrolled or planning to enroll in a research study that would conflict with full participation in the current study or confound the observation or interpretation of the study findings
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cholecalciferol Dose II
Oral suspension cholecalciferol 400,000 IU
|
7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
|
Placebo Comparator: Placebo
Oral suspension of placebo cholecalciferol
|
7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
|
Active Comparator: Cholecalciferol Dose I
Oral suspension cholecalciferol 200,000 IU
|
7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Vitamin D Status 5 Days Following Supplementation With Cholecalciferol
Time Frame: Patients will be followed between the onset of suspected sepsis and for an average duration of 7 days
|
Subjects will receive 200,000 IU or 400,000 IU cholecalciferol suspension (vs.
placebo) within 24 hours from the onset of a suspected case of sepsis during their hospitalization.
Vitamin D status at the onset of a suspected case of sepsis will be compared to vitamin D status between 5-9 days after supplementation with cholecalciferol or placebo.
To assess vitamin D status, we will measure serum and urine: 1) 25-hydroxyvitamin D; 2) 1,25-dihydroxyvitamin D; 3) 24,25-dihydroxyvitamin D; 4) Fibroblast growth factor 23; 5) Vitamin D binding protein; 6) LL-37; 7) Parathyroid hormone; 8) Albumin; 9) Calcium; and 10) Phosphorus levels.
|
Patients will be followed between the onset of suspected sepsis and for an average duration of 7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Immunological Profile 5 Days Following Supplementation With Cholecalciferol
Time Frame: Patients will be followed between the onset of suspected sepsis and for an average duration of 7 days
|
Subjects will receive 200,000 IU or 400,000 IU cholecalciferol suspension (vs.
placebo) within 24 hours from the onset of a suspected case of sepsis during their hospitalization.
Immunological profile at the onset of a suspected case of sepsis will be compared to the immunological profile between 5-9 days after supplementation with cholecalciferol or placebo.
To assess the immunological profile, we will measure serum LL-37.
|
Patients will be followed between the onset of suspected sepsis and for an average duration of 7 days
|
Incidence of Infection-related Complications Within 90 Days From the Onset of a Suspected Case of Sepsis
Time Frame: Patients will be followed between the onset of suspected sepsis and for an average duration of 90 days
|
Subjects will receive 200,000 IU or 400,000 IU cholecalciferol suspension (vs.
placebo) within 24 hours from the onset of a suspected case of sepsis during their hospitalization.
The incidence of infection-related complications will be assessed between the onset of suspected sepsis and 80-100 days after supplementation with cholecalciferol or placebo.
To assess the incidence of infection-related complications, we will measure rates of: 1) ICU length of stay; and 2) hospital length of stay
|
Patients will be followed between the onset of suspected sepsis and for an average duration of 90 days
|
Incidence of Infection-related Complications Within 90 Days From the Onset of a Suspected Case of Sepsis
Time Frame: Patients will be followed between the onset of suspected sepsis and for an average duration of 90 days
|
Subjects will receive 200,000 IU or 400,000 IU cholecalciferol suspension (vs. placebo) within 24 hours from the onset of a suspected case of sepsis during their hospitalization. The incidence of infection-related complications will be assessed between the onset of suspected sepsis and 80-100 days after supplementation with cholecalciferol or placebo. To assess the incidence of infection-related complications, we will measure rates of: 1) 30 day hospital readmission; and 2) 30 day mortality. |
Patients will be followed between the onset of suspected sepsis and for an average duration of 90 days
|
Change in Immunological Profile 5 Days Following Supplementation With Cholecalciferol
Time Frame: Patients will be followed between the onset of suspected sepsis and for an average duration of 90 days
|
Subjects will receive 200,000 IU or 400,000 IU cholecalciferol suspension (vs.
placebo) within 24 hours from the onset of a suspected case of sepsis during their hospitalization.
Immunological profile at the onset of a suspected case of sepsis will be compared to the immunological profile between 5-9 days after supplementation with cholecalciferol or placebo.
To assess the immunological profile, we will measure serum hsCRP.
|
Patients will be followed between the onset of suspected sepsis and for an average duration of 90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sadeq A Quraishi, MD, MHA, MMSc, Harvard Medical School, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Metabolic Diseases
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Nutrition Disorders
- Musculoskeletal Diseases
- Deficiency Diseases
- Malnutrition
- Bone Diseases
- Bone Diseases, Metabolic
- Calcium Metabolism Disorders
- Sepsis
- Vitamin D Deficiency
- Rickets
- Avitaminosis
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
- 2013P001406
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypovitaminosis D
-
Hospices Civils de LyonCompleted
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Silvana De Giorgi; Davide Bizzoca; Angela NotarnicolaRecruitingHypovitaminosis DItaly
-
Madigan Army Medical CenterCompletedHypovitaminosis DUnited States
-
University of TromsoCompleted
-
Jewish General HospitalMcGill UniversityCompleted
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Completed
-
Massachusetts General HospitalBio-Tech Pharmacal, Inc.CompletedHypovitaminosis DUnited States
-
Boston UniversityCompletedVitamin D Deficiency | Vitamin E Deficiency | Hypovitaminosis AUnited States
-
Harokopio UniversityUniversity College Cork; FrieslandCampinaCompletedHypovitaminosis D | Deficiency of MicronutrientsGreece
-
Chulalongkorn UniversityUnknownVitamin D2 Supplementation in Vitamin D InsufficiencyThailand
Clinical Trials on Cholecalciferol
-
Medical University of South CarolinaTerminatedVitamin D Deficiency | Nutritional DeficiencyUnited States
-
Centre of Postgraduate Medical EducationUnknownInfant, Premature, DiseasesPoland
-
Johns Hopkins UniversityNational Institute on Aging (NIA)TerminatedVitamin D Deficiency | FallsUnited States
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedCystic Fibrosis | Allergic Bronchopulmonary AspergillosisUnited States
-
Rashid Centre for Diabetes and ResearchCompletedObesity | Type 2 Diabetes Mellitus | Hypovitaminosis DUnited Arab Emirates
-
University Hospitals Cleveland Medical CenterUniversity of Colorado, DenverCompletedInflammationUnited States
-
University Hospital, AngersMylan LaboratoriesCompleted
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Assistance Publique - Hôpitaux de ParisLaboratoire CrinexCompletedRenal Transplant Candidate for Right KidneyFrance